Gene panel of biomarkers to diagnose metastatic liver cancer
This invention addresses an unmetmedical need – liver cancer patients resistant to standard chemotherapy. Thisnovel gene panel adds a more accurate option to the standard AFP baseddiagnosis; because the gene panel is already identified, diagnosis can be donerelatively quickly (within one day), relatively cheaply (cost can be controlledat around $500) and less invasive (blood sample can be used). Moreover, on-the-markettreatment options are identified for liver cancer patients diagnosed using suchgene panel.
Hepatocellular carcinoma (HCC) is the third most deadly cancer and not all patients respond to standard chemotherapy. USC researchers discovered a gene panel that can be used for personalized diagnosis, especially for chemo-resistant patients.
美國
